ArticleMolecular therapy. Nucleic acids2026
To scramble or not: Steric blocking 2'-MOE/PS control antisense oligonucleotides across cellular models.
Article in Molecular therapy. Nucleic acids, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antisense oligonucleotides (ASOs) are emerging as a promising therapeutic approach for many disorders. Currently, fourteen ASOs have been FDA/EMA-approved, with many more in preclinical development. An important requirement for preclinical studies is the inclusion of negative controls to properly assess the efficacy of candidate ASOs. As commonly used scrambled or sense ASOs may elicit unwanted off-target effects that could influence downstream data analysis, there is a high need for the inclusion of additional negative control ASOs (cASOs) that are well-characterized and well-tolerated. In this study, we designed and evaluated generic cASOs across seven different cellular models. Characterization at the RNA and protein level revealed potential ASO toxicity mechanisms as well as species-specific and cell-type-specific effects. In total, three steric blocking 2'-MOE/PS cASOs with a distinct GC content were identified that exert limited off-target effects across all cellular models. To conclude, we report a set of cASOs that are potentially applicable in a broad variety of experiments using ASOs with similar physicochemical properties and across different cellular models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.